EMERGENT BIOSOLUTIONS INC. Goodwill, Foreign Currency Translation Gain (Loss)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Goodwill, Foreign Currency Translation Gain (Loss) of $0 for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-12-11.
Discontinued › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2023-12-11
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2022-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2022-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for fiscal 2022 was $0.00.
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for fiscal 2021 was -$100.00K, a 200.00% decline from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. goodwill, foreign currency translation gain (loss) for fiscal 2020 was $100.00K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $0.00 derived: sum of 2 quarters · filed 2023-12-11 | $0.00 derived: sum of 3 quarters · filed 2023-12-11 | $0.00 10-K/A · filed 2023-12-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $100.00K derived: sum of 4 quarters · filed 2023-12-11 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 | $100.00K derived: sum of 3 quarters · filed 2023-12-11 | $0.00 derived: sum of 4 quarters · filed 2023-12-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-04-29 | $100.00K derived: sum of 2 quarters · filed 2023-12-11 | $0.00 derived: sum of 3 quarters · filed 2023-12-11 | $100.00K derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-12-31 | $100.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $0.00 derived: sum of 2 quarters · filed 2023-12-11 | $100.00K derived: sum of 3 quarters · filed 2023-12-11 | -$100.00K 10-K/A · filed 2023-12-11 |
| 2021-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | -$200.00K 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | -$100.00K 10-Q · filed 2021-07-30 | ||
| 2021-03-31 | -$200.00K 10-Q · filed 2021-04-30 | |||
| 2020-12-31 | $100.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |